At 6 months, the arm receiving chemotherapy selected by ChemoID had an ORR of 55%, compared with 5% in the physician choice arm.
A chemotherapeutic assay (ChemoID) designed to to select targeted treatments for patients with platinum-resistant ovarian cancer, based on the cytotoxicity profile of patients’ cancer stem cells, significantly improved objective response rates (ORRs), according to data from a phase 3 trial (NCT03949283) published in npj Precision Oncology.1
In the multicenter trial 81 patients were randomized 1:1 to be treated with 1 of 13 preselected chemotherapy regimens that was either assigned by the ChemoID assay (n = 34) or by physician’s choice (n = 41). The primary end point was ORR as determined by CT scans using RECIST 1.1 criteria at 6 months. The ChemoID arm experienced an ORR of 55% (95% CI,…